Psychiatry and Neurology, Neurology · Dallas, TX
NPI
1740591668
Since 2010
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
8390 Lyndon B Johnson Fwy Ste 1000
Dallas, TX, 75243
Phone (214) 750-1510
Groups this clinician bills Medicare through
Medicare paid, 2024
$501K
28,730 services
Medicare patients, 2024
672
Average age 76
Drug cost, 2024
$4.2M
3,556 prescriptions
Company payments, 2025
$345K
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nirav Pavasia was code J0588 (injection, incobotulinumtoxin a, 1 unit), 5,929 times for 17 patients. In total Nirav Pavasia billed 28,730 services in 78 codes, and Medicare paid $501K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 5,929 | 17 | $4.08 | $24K |
| J0586 Injection, abobotulinumtoxina, 5 units | Office | 5,541 | 14 | $6.85 | $38K |
| J0587 Injection, rimabotulinumtoxinb, 100 units | Office | 1,826 | 13 | $9.36 | $17K |
| 97112 PT Treatment | Office | 1,135 | 69 | $21.22 | $24K |
| 99215 Office E&M - Established | Office | 805 | 415 | $134.20 | $108K |
| 97530 PT Treatment | Office | 789 | 68 | $24.36 | $19K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 741 | 432 | $12.40 | $9,186 |
| 97110 PT Treatment | Office | 607 | 64 | $17.55 | $11K |
| A9575 Injection, gadoterate meglumine, 0.1 ml | Office | 491 | 36 | $0.09 | $45.82 |
| 97130 Behavioral Health Services | Office | 467 | 27 | $16.93 | $7,908 |
| 99214 Office E&M - Established | Office | 275 | 193 | $95.51 | $26K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 265 | 48 | $48.18 | $13K |
| 97150 PT Treatment | Office | 231 | 53 | $10.93 | $2,524 |
| 95984 Electrical Nerve Conductivity | Office | 225 | 50 | $33.94 | $7,636 |
| 97129 Behavioral Health Services | Office | 210 | 27 | $17.73 | $3,724 |
By year: 2022 $300K for 18,960 services; 2023 $338K for 19,754 services; 2024 $501K for 28,730 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nirav Pavasia prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 620 prescriptions and refills. In total Nirav Pavasia wrote 3,556 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 620 | 1,590 | 219 | $30K |
| Nuplazid Pimavanserin Tartrate | 190 | 219 | 29 | $1.1M |
| Rytary Carbidopa/Levodopa | 176 | 371 | 39 | $412K |
| Gabapentin Generic | 145 | 361 | 50 | $3,926 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 132 | 358 | 48 | $17K |
| Gocovri Amantadine Hcl | 119 | 151 | 14 | $329K |
| Clonazepam Generic | 109 | 134 | 38 | $1,959 |
| Ingrezza Valbenazine Tosylate | 109 | 121 | 14 | $1.1M |
| Donepezil Hcl Generic | 99 | 278 | 37 | $1,388 |
| Primidone Generic | 95 | 274 | 37 | $5,472 |
| Nourianz Istradefylline | 94 | 128 | 18 | $242K |
| Ongentys Opicapone | 83 | 133 | 18 | $89K |
| Bupropion Hcl Sr Bupropion Hcl | 80 | 177 | 23 | $3,124 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 73 | 177 | 25 | $1,916 |
| Memantine Hcl Generic | 66 | 137 | 23 | $1,957 |
Brand drugs: 1,030 claims; generic drugs: 2,526 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nirav Pavasia $345K ($345K in general payments such as food, travel and fees) from 36 companies. The largest payer was MDD US Operations, LLC with $96K.
| Company | Payments | Amount |
|---|---|---|
| MDD US Operations, LLC | 78 | $96K |
| Neurocrine BioSciences, Inc. NBIX | 90 | $66K |
| Abbvie Inc. ABBV | 62 | $52K |
| ACADIA Pharmaceuticals Inc ACAD | 93 | $42K |
| Teva Pharmaceuticals USA, Inc. TEVA | 58 | $41K |
| Amneal Pharmaceuticals LLC AMRX | 16 | $33K |
| Boston Scientific Corporation BSX | 39 | $12K |
| Abbott Laboratories ABT | 11 | $157 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $126 |
| Biogen, Inc. BIIB | 5 | $107 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.